Research

Donanemab (brand name Kisunla) is a new medicine approved to treat people with early-stage Alzheimer’s disease, specifically those with mild cognitive impairment or mild dementia. It works by helping the body clear amyloid plaques from the brain, which are thought to play a role in Alzheimer’s disease.[1][2] In this blog we will discuss clinical trial TRAILBLAZER-ALZ 2 which studied Donanemab infusions and its benefits and risks in early Alzheimers patients. In this large cli

Five science-backed tips for improving brain health and slowing cognitive decline.